Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ocedurenone
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Novo Nordisk
Deal Size : $1,300.0 million
Deal Type : Acquisition
Novo Nordisk to Acquire Ocedurenone for Uncontrolled Hypertension from KBP Biosciences
Details : Through the acquisition, Novo Nordisk gains access to KBP-5074 (ocedurenone), an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist (nsMRA), for uncontrolled hypertension with potential application in cardiovascular ...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 16, 2023
Lead Product(s) : Ocedurenone
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Novo Nordisk
Deal Size : $1,300.0 million
Deal Type : Acquisition
Lead Product(s) : Ocedurenone
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KBP-5074 (ocedurenone) is a non-steroidal MRA which selectively binds to recombinant human MRs with much higher affinity than to recombinant human glucocorticoid, progesterone, and androgen receptors which can produce antihypertensive, renal and cardiopr...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 01, 2023
Lead Product(s) : Ocedurenone
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KBP-7072
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of KBP-7072 in Healthy Male and Female Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 19, 2022
Lead Product(s) : KBP-7072
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KBP-5074
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 20, 2021
Lead Product(s) : KBP-5074
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KBP-5074
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Covance
Deal Size : Inapplicable
Deal Type : Inapplicable
Mass Balance Study of KBP-5074 in Healthy Male Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 18, 2020
Lead Product(s) : KBP-5074
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Covance
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Itraconazole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Covance
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 28, 2020
Lead Product(s) : Itraconazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Covance
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ocedurenone
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Labcorp Drug Development
Deal Size : Inapplicable
Deal Type : Inapplicable
KBP Biosciences Announces Data Presentation at the American Society of Nephrology Annual Meeting
Details : The upcoming data to be presented at the American Society of Nephrology (ASN) Annual Meeting showcases a pre-clinical study investigating the effect of KBP-5074 on aldosterone-mediated renal injury in the uninephrectomized SD rat CKD model.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 22, 2020
Lead Product(s) : Ocedurenone
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Labcorp Drug Development
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KBP-5074
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Covance
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 01, 2020
Lead Product(s) : KBP-5074
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Covance
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KBP-7072
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Covance
Deal Size : Inapplicable
Deal Type : Inapplicable
A Multiple Ascending Dose Study to Investigate Safety of KBP-7072 in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 31, 2020
Lead Product(s) : KBP-7072
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Covance
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ocedurenone
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 2b clinical trial met its primary endpoint, with KBP-5074 demonstrating a clinically and statistically significant improvement in systolic blood pressure (SBP) from baseline to day 84 in Stage 3b/4 CKD patients with uncontrolled hypertension.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 12, 2020
Lead Product(s) : Ocedurenone
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable